CureVac and Bayer strike deal over Covid-19 vaccine
CureVac, which had said it was looking for a larger partner, started a late-stage clinical trial of its Covid-19 vaccine candidate in December
07 January 2021 - 10:54
Berlin — German biotech firm CureVac has agreed an alliance with drugmaker Bayer to help it seek regulatory approval for its experimental Covid-19 vaccine and distribute doses, the two companies said on Thursday.
“Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance as well as support in selected countries,” they said...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.